Literature DB >> 11689986

Paraplegia secondary to Burkholderia pseudomallei myelitis: a case report.

M J Haran1, A W Jenney, R J Keenan, H D Flavell, N M Anstey, B J Currie.   

Abstract

Bacterial infection is an uncommon cause of acute paraplegia. A 42-year-old Aboriginal man presented to a remote health clinic in northern Australia with myelitis associated with Burkholderia pseudomallei. He was treated with analgesia and intravenous flucloxacillin, ceftriaxone, and gentamicin and transferred to our hospital, where an urgent T12-L1 laminectomy and decompression was performed. Urine culture confirmed B. pseudomallei infection (melioidosis). Abdominopelvic computed tomography revealed left prostatic lobe and right periprostatic abscesses, which were managed conservatively. The patient was given intravenous ceftazidime (8g/d) for 2 months, followed by oral sulfamethoxazole (1600mg) and trimethoprim (320mg) twice daily for 8 weeks. Magnetic resonance imaging 3 weeks after his admission confirmed transverse myelitis. His rehabilitation was complicated by his difficulty in adjusting to disability, by urinary retention and fecal incontinence, by communication barriers, and his isolation from a culture familiar to him. He returned to his community after 15 weeks, free of infection, with T10-11 paraplegia and an indwelling catheter. Copyright 2001 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation

Entities:  

Mesh:

Year:  2001        PMID: 11689986     DOI: 10.1053/apmr.2001.25074

Source DB:  PubMed          Journal:  Arch Phys Med Rehabil        ISSN: 0003-9993            Impact factor:   3.966


  2 in total

1.  Transverse myelitis secondary to melioidosis: a case report.

Authors:  Shanika Nandasiri; Harith Wimalaratna; Muditha Manjula; Enoka Corea
Journal:  BMC Infect Dis       Date:  2012-09-28       Impact factor: 3.090

2.  Neurotropic threat characterization of Burkholderia pseudomallei strains.

Authors:  Jodie Morris; Anne Fane; Catherine Rush; Brenda Govan; Mark Mayo; Bart J Currie; Natkunam Ketheesan
Journal:  Emerg Infect Dis       Date:  2015-01       Impact factor: 6.883

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.